Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD4785 · 1 trial · 2 indications
Determined through the evaluation of dose-limiting toxicity (DLT), adverse events, clinical laboratory test results, clinical evaluation and patient reported symptoms
| Arm | Type | Description |
|---|---|---|
| AZD4785 | EXPERIMENTAL | This is a single-arm study in which all patients will receive AZD4785 by IV infusion. Patients will continue to receive treatment with AZD4785 until disease progression, intolerable toxicity, or discontinuation criteria are met. |
| Name | Type | Description |
|---|---|---|
| AZD4785 | DRUG | KRAS Antisense Oligonucleotide |
Inclusion Criteria Part A Dose Escalation: Patients must have histological or cytological confirmation of a solid tumour known to harbour KRAS mutations (e.g., NSCLC, mCRC, pancreatic or cholangiocarcinoma), and have progressed despite standard therapy(ies), or are intolerant to standard therapy(ie...
Top 20 of 90 competitors
AZD4785 is an investigational small molecule developed for the treatment of non-small cell lung cancer and other advanced solid tumors. It was studied in a Phase 1 dose-escalation trial in adults with advanced disease. It is not an approved therapy and remains in clinical development.
AZD4785 is developed by AstraZeneca PLC, which trades on the Nasdaq under the ticker AZN. AstraZeneca sponsored the Phase 1 dose-escalation study of the compound in patients with advanced solid tumors, including non-small cell lung cancer.
AZD4785 is in Phase 1 development. One Phase 1 dose-escalation trial has been completed, and no trials of the drug are currently active. The study enrolled 28 patients and was conducted in the United States and the United Kingdom.
AZD4785 was evaluated in one Phase 1 trial, NCT03101839, titled a Phase I Dose-Escalation Study of AZD4785 in Patients With Advanced Solid Tumours. The trial enrolled 28 adults, was uncontrolled and open-label, and has completed. It included patients with non-small cell lung cancer and advanced solid tumors.
AZD4785 is not approved. It is an investigational agent that has completed a single Phase 1 dose-escalation trial in advanced solid tumors, including non-small cell lung cancer. No active trials of AZD4785 are ongoing, and the compound remains in early clinical development.
Yes. The Phase 1 trial of AZD4785, NCT03101839, was biomarker-selected, meaning enrollment was guided by a molecular biomarker rather than an unselected patient population. The study enrolled 28 adults with advanced solid tumors, including non-small cell lung cancer, across sites in the United States and the United Kingdom.